DeepSomatic: a neural network for somatic variants in tumors
For insertions and deletions, it reaches 90% with Illumina data versus 80% for the best other tool, and over 80% with PacBio versus under 50%. In eight pediatric leukemia samples, it recovered known variants and flagged ten new ones that have not been independently validated. The tool and CASTLE dataset are open.
Technology: DeepSomatic (convolutional neural network)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: DeepSomatic was benchmarked against SomaticSniper, MuTect2, Strelka2 and ClairS on the CASTLE cell-line dataset with held-out chromosomes and genomes, across Illumina, PacBio and other platforms.
- Still unknown: The benchmark uses research cell lines rather than patient tumors, the glioblastoma result rests on one sample, and the 10 new leukemia variants are not stated to be validated.
- AI role: A convolutional neural network applied to sequencing data converted to images separated germline, somatic and error signals to call tumor variants.
Evidence sources: https://research.google/blog/using-ai-to-identify-genetic-variants-in-tumors-with-deepsomatic/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41587-025-02839-x&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 59 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.